Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNY OTCMKTS:GNMSF NASDAQ:GRFS OTCMKTS:MKGAF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$297.45-1.0%$311.16$284.19▼$495.55$39.71B0.311.08 million shs681,280 shsGNMSFGenmab A/S$258.12-4.2%$269.72$198.51▼$352.00$15.89B0.825,707 shs3 shsGRFSGrifols$7.98-1.6%$8.05$7.39▼$11.14$5.52B0.68617,819 shs379,991 shsMKGAFMerck KGaA$151.34+1.4%$132.87$116.68▼$159.34$21.87B0.96673 shs1,036 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals-1.02%+3.65%-4.23%-11.52%+1.66%GNMSFGenmab A/S-4.22%-2.70%-5.04%-9.24%+23.89%GRFSGrifols-1.60%+4.18%-4.89%-15.11%-2.56%MKGAFMerck KGaA+1.43%+5.91%+9.75%-0.90%+15.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$297.45-1.0%$311.16$284.19▼$495.55$39.71B0.311.08 million shs681,280 shsGNMSFGenmab A/S$258.12-4.2%$269.72$198.51▼$352.00$15.89B0.825,707 shs3 shsGRFSGrifols$7.98-1.6%$8.05$7.39▼$11.14$5.52B0.68617,819 shs379,991 shsMKGAFMerck KGaA$151.34+1.4%$132.87$116.68▼$159.34$21.87B0.96673 shs1,036 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals-1.02%+3.65%-4.23%-11.52%+1.66%GNMSFGenmab A/S-4.22%-2.70%-5.04%-9.24%+23.89%GRFSGrifols-1.60%+4.18%-4.89%-15.11%-2.56%MKGAFMerck KGaA+1.43%+5.91%+9.75%-0.90%+15.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNYAlnylam Pharmaceuticals 2.85Moderate Buy$463.1355.70% UpsideGNMSFGenmab A/S 0.00N/AN/AN/AGRFSGrifols 1.75Reduce$10.0025.31% UpsideMKGAFMerck KGaA 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GNMSF, ALNY, MKGAF, and GRFS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026ALNYAlnylam Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$380.005/18/2026ALNYAlnylam Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/8/2026GRFSGrifols Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/8/2026GRFSGrifols Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/5/2026ALNYAlnylam Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$510.005/4/2026ALNYAlnylam Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/1/2026ALNYAlnylam Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$450.00 ➝ $445.005/1/2026ALNYAlnylam Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$376.00 ➝ $377.004/13/2026ALNYAlnylam Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$515.00 ➝ $505.004/6/2026ALNYAlnylam Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)3/27/2026GRFSGrifols Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNYAlnylam Pharmaceuticals$4.29B9.26$2.77 per share107.47$8.05 per share36.95GNMSFGenmab A/S$3.72B4.27$14.99 per share17.22$92.29 per share2.80GRFSGrifols$7.44B0.73$1.39 per share5.73$13.49 per share0.59MKGAFMerck KGaA$22.72B0.86$45.58 per share3.32$212.00 per share0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNYAlnylam Pharmaceuticals$313.75M$3.6681.2728.96N/A11.72%85.76%10.32%7/30/2026 (Estimated)GNMSFGenmab A/S$963M$13.2619.47N/AN/A21.05%15.34%8.94%8/6/2026 (Estimated)GRFSGrifols$454.82M$0.1942.005.960.315.54%6.21%2.39%7/23/2026 (Estimated)MKGAFMerck KGaA$3.06B$6.8123.1114.35N/A12.60%10.17%5.74%8/6/2026 (Estimated)Latest GNMSF, ALNY, MKGAF, and GRFS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2026Q1 2026ALNYAlnylam Pharmaceuticals$0.8720$1.99+$1.1180$1.51$1.12 billion$1.17 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALNYAlnylam PharmaceuticalsN/AN/AN/AN/AN/AGNMSFGenmab A/SN/AN/AN/AN/AN/AGRFSGrifols$0.141.75%N/A73.68%N/AMKGAFMerck KGaAN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNYAlnylam Pharmaceuticals0.943.133.06GNMSFGenmab A/S0.872.182.17GRFSGrifols1.162.470.85MKGAFMerck KGaA0.271.310.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNYAlnylam Pharmaceuticals92.97%GNMSFGenmab A/SN/AGRFSGrifolsN/AMKGAFMerck KGaA0.10%Insider OwnershipCompanyInsider OwnershipALNYAlnylam Pharmaceuticals0.86%GNMSFGenmab A/S1.54%GRFSGrifols0.19%MKGAFMerck KGaAN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNYAlnylam Pharmaceuticals2,770133.51 million132.37 millionOptionableGNMSFGenmab A/S3,02961.57 million60.62 millionNot OptionableGRFSGrifols25,247680.58 million679.28 millionOptionableMKGAFMerck KGaA62,908129.24 millionN/ANot OptionableGNMSF, ALNY, MKGAF, and GRFS HeadlinesRecent News About These CompaniesShould Value Investors Buy Merck KGaA (MKKGY) Stock?May 18, 2026 | zacks.comEvotec (OTCMKTS:EVTCY) and Merck KGaA (OTCMKTS:MKGAF) Head-To-Head AnalysisMay 16, 2026 | americanbankingnews.comMerck KGaA (MKGAF) Q1 2026 Earnings Call Highlights: Strong Start with Life Science and ...May 14, 2026 | uk.finance.yahoo.comMerck KGaA (MKKGY) Surpasses Q1 Earnings and Revenue EstimatesMay 13, 2026 | zacks.comMerck KGaA (MKGAF) to Release Earnings on WednesdayMay 6, 2026 | marketbeat.comMerck KGaA (OTCMKTS:MKGAF) Sees Strong Trading Volume - Here's WhyMay 4, 2026 | marketbeat.comMerck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin ManifestationsApril 30, 2026 | businesswire.comMerck KGaA (OTCMKTS:MKGAF) Shares Gap Down - Time to Sell?April 29, 2026 | marketbeat.comMerck KGaA (OTCMKTS:MKGAF) Sees Strong Trading Volume - Time to Buy?April 27, 2026 | marketbeat.comMerck KGaA (OTCMKTS:MKGAF) Shares Down 9.3% - Time to Sell?April 23, 2026 | marketbeat.comHead-To-Head Analysis: Merck KGaA (OTCMKTS:MKGAF) vs. Athersys (NASDAQ:ATHX)March 28, 2026 | defenseworld.netDAfter generic defense fails, Merck KGaA assumes no US Mavenclad sales after MarchMarch 5, 2026 | fiercepharma.comFMerck KGaA falls on lackluster guidance for 2026March 5, 2026 | seekingalpha.comMerck KGaA (MKGAF) Q4 2025 Earnings Call Highlights: Resilient Growth Amidst ChallengesMarch 5, 2026 | finance.yahoo.comGermany’s Merck KGaA Expects Currency Headwinds to Weigh on EarningsMarch 5, 2026 | wsj.comMerck KGaA sees earnings decline of up to 4%March 5, 2026 | globalbankingandfinance.comGMerck KGaA Flags 2026 Earnings Drop as Mavenclad Faces GenericsMarch 5, 2026 | bloomberg.comSanofi shocker: CEO Paul Hudson out as board demands 'increased rigor'February 12, 2026 | msn.comSanofi replaces CEO Paul Hudson with outgoing Merck KGaA headFebruary 12, 2026 | finance.yahoo.comSanofi Names Merck KGaA's Garijo to Replace Hudson as CEOFebruary 12, 2026 | wsj.comMerck KGaA - depositary receipt (MKKGY) price target increased by 16.64% to 57.45February 4, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNMSF, ALNY, MKGAF, and GRFS Company DescriptionsAlnylam Pharmaceuticals NASDAQ:ALNY$297.45 -3.06 (-1.02%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$298.91 +1.46 (+0.49%) As of 05/22/2026 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Genmab A/S OTCMKTS:GNMSF$258.12 -11.38 (-4.22%) As of 05/22/2026 09:30 AM EasternGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Grifols NASDAQ:GRFS$7.98 -0.13 (-1.60%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.92 -0.06 (-0.69%) As of 05/22/2026 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.Merck KGaA OTCMKTS:MKGAF$151.34 +2.13 (+1.43%) As of 05/22/2026 03:54 PM EasternMerck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
